In this article
Ipamorelin vs sermorelin is mainly a difference in receptor: ipamorelin is a ghrelin-receptor agonist (a GHRP), while sermorelin is a growth hormone-releasing hormone (GHRH) analogue. Tesamorelin is also a GHRH analogue, but it is the one with an approved indication and the deepest trial evidence, specifically for visceral fat.
- Ipamorelin acts on the ghrelin receptor; sermorelin and tesamorelin act on the GHRH receptor.
- All three stimulate the pituitary to release its own growth hormone, rather than supplying GH directly.
- Tesamorelin has randomized trial data in HIV-associated lipodystrophy; ipamorelin and sermorelin have far less outcome-based human evidence for body-composition goals.
- Signal IQ’s research ranges are daily subcutaneous doses between 500 mcg and 2 mg depending on the compound, and none is a personal recommendation.
Ipamorelin vs sermorelin vs tesamorelin: comparison table
| Feature | Ipamorelin | Sermorelin | Tesamorelin |
|---|---|---|---|
| Class | GHRP, ghrelin mimetic (five amino acids) | GHRH analogue (first 29 amino acids of GHRH) | GHRH analogue (modified, longer-lasting) |
| Receptor | Ghrelin / GH secretagogue receptor | GHRH receptor | GHRH receptor |
| Best-known evidence | Selectivity for GH release; limited outcome trials | Historical diagnostic and clinical use; limited recent trials | Randomized placebo-controlled trials on visceral fat |
| Regulatory status | Not approved | Previously approved for diagnostic use; now research or compounded | Approved for HIV-associated lipodystrophy |
| Research dose range (Signal IQ) | 500 mcg to 1 mg daily | 500 mcg to 1 mg daily | 500 mcg to 1 mg daily reference; 1 to 2 mg in trial-style protocols |
| Reported cycle | 12 to 16 weeks on, about 4 off | 12 weeks on, 4 off | 4 to 5 months on, 4 weeks off |
| Commonly paired with | CJC-1295 or sermorelin | A GHRP such as ipamorelin | Sometimes ipamorelin |
Pages for each: ipamorelin, sermorelin, tesamorelin.
Ipamorelin vs sermorelin
Sermorelin copies the first 29 amino acids of natural GHRH, binding the GHRH receptor on pituitary somatotroph cells and keeping normal feedback loops intact. Ipamorelin mimics ghrelin and acts through a different receptor, with the pituitary again releasing its own GH.
Because the receptors differ, the two are often discussed as complementary: sermorelin standalone or paired with a GHRP such as ipamorelin. Ipamorelin is described as selective, with little effect on cortisol or prolactin and minimal appetite stimulation compared with older GHRPs. Sermorelin’s short action means it is typically dosed once daily, often before bed to coincide with the natural overnight GH pulse.
Ipamorelin vs tesamorelin
Tesamorelin is a longer-lasting GHRH analogue; ipamorelin is a GHRP. The practical difference is evidence: tesamorelin was developed for a defined condition and studied in randomized trials, while ipamorelin’s appeal rests on selectivity and mechanism.
Summaries of tesamorelin’s trials in HIV-associated lipodystrophy report visceral fat falling by roughly 15% over 26 weeks versus about 5% on placebo, with IGF-1 rising but staying within the normal range, and visceral fat returning after stopping. These figures come from a secondary source and should be checked against the primary publications. They apply to that population, not to general use.
Tesamorelin vs sermorelin
Both act on the GHRH receptor, but they are not interchangeable. Tesamorelin is a modified molecule with greater stability and an approved indication. Sermorelin is the unmodified 29-amino-acid fragment with a short duration. For visceral fat specifically, tesamorelin has the strongest trial support of any peptide in this group, while sermorelin’s evidence is mostly historical, animal or case-based.
Which growth hormone peptide is best?
No single one is best. The right comparison depends on what is being studied and which evidence matters.
- Strongest human trial evidence: tesamorelin, for visceral fat in a defined population.
- Most selective GH release: ipamorelin, by mechanism.
- Closest to natural GHRH: sermorelin.
Claims about sleep, skin, recovery and anti-aging are mostly extrapolated from raising GH and IGF-1 and are not firmly established by outcome trials. To explore by goal, use peptides by goal, or ask Pulse.
Sermorelin benefits
Sermorelin benefits discussed in the literature relate to stimulating endogenous GH while keeping feedback regulation, which is why sleep quality, body composition and recovery are commonly cited. Sleep improvements are the most often reported early effect; body-composition claims are weaker. Treat anecdotal timelines with caution.
Other reported topics, including immune function, bone density and libido, are not backed by strong controlled data in this context.
Side effects and precautions
- Water retention is the effect named most often in research protocols; the usual response is lowering the dose and re-titrating slowly.
- Injection-site reactions, flushing and mild headache or dizziness are described across the class.
- Tesamorelin trials also reported joint or muscle aches and, rarely, carpal-tunnel-like symptoms, with glucose worth monitoring.
- Active cancer, pregnancy and diabetes are common cautions, since GH-axis stimulation affects growth and glucose.
Baseline IGF-1 and glucose can be planned with the Bloodwork Panel Planner. See also CJC-1295 DAC vs no DAC, the CJC-1295 and ipamorelin stack, and peptides for muscle growth.
Frequently asked questions
What is the difference between ipamorelin and sermorelin?
Ipamorelin acts on the ghrelin receptor; sermorelin is a GHRH analogue acting on the GHRH receptor. Both prompt the pituitary to release GH.
Is tesamorelin better than sermorelin?
Tesamorelin has far stronger trial evidence for visceral fat and an approved indication; sermorelin is the shorter-acting, unmodified fragment.
Which growth hormone peptide is best?
None is universally best. It depends on the goal and evidence needed; tesamorelin has the deepest trial data, ipamorelin the most selective mechanism.
Can ipamorelin and sermorelin be combined?
They are often paired because they use different receptors, though controlled combination data are limited.
Are these peptides the same as HGH?
No. They stimulate the pituitary to release its own GH, unlike direct HGH. See IGF-1 LR3 vs HGH.
Go deeper on Signal IQ
Still have questions? Ask Pulse, Signal IQ’s free AI research assistant, or compare doses in the Peptide Dosage Chart.
Ask PulseEducational content only. Nothing here is medical advice or a recommendation to use any compound. Many peptides discussed are research compounds not approved for human use. Talk to a qualified clinician about your situation. Signal IQ does not sell peptides.



